These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 33866066)

  • 1. Combination therapy in inflammatory bowel disease - from traditional immunosuppressors towards the new paradigm of dual targeted therapy.
    Privitera G; Pugliese D; Onali S; Petito V; Scaldaferri F; Gasbarrini A; Danese S; Armuzzi A
    Autoimmun Rev; 2021 Jun; 20(6):102832. PubMed ID: 33866066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy in inflammatory bowel disease: Current evidence and perspectives.
    Dai C; Huang YH; Jiang M
    Int Immunopharmacol; 2023 Jan; 114():109545. PubMed ID: 36508920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thiopurines and inflammatory bowel disease: Current evidence and a historical perspective.
    Axelrad JE; Roy A; Lawlor G; Korelitz B; Lichtiger S
    World J Gastroenterol; 2016 Dec; 22(46):10103-10117. PubMed ID: 28028358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of Biological Agents in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Case Series and Review of the Literature.
    Olbjørn C; Rove JB; Jahnsen J
    Paediatr Drugs; 2020 Aug; 22(4):409-416. PubMed ID: 32378002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease.
    Renna S; Cottone M; Orlando A
    World J Gastroenterol; 2014 Aug; 20(29):9675-90. PubMed ID: 25110407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual Biologic and Small Molecule Therapy for the Treatment of Refractory Pediatric Inflammatory Bowel Disease.
    Dolinger MT; Spencer EA; Lai J; Dunkin D; Dubinsky MC
    Inflamm Bowel Dis; 2021 Jul; 27(8):1210-1214. PubMed ID: 33125058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Considerations Regarding the Use of Thiopurines in Older Patients with Inflammatory Bowel Disease.
    Calafat M; Mañosa M; Cañete F; Domènech E
    Drugs Aging; 2021 Mar; 38(3):193-203. PubMed ID: 33438138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Visceral adiposity and inflammatory bowel disease.
    Rowan CR; McManus J; Boland K; O'Toole A
    Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of the combination of biologics and/or small molecules in the treatment of patients with inflammatory bowel disease.
    Balderramo D
    World J Gastroenterol; 2022 Dec; 28(47):6743-6751. PubMed ID: 36620336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologics in inflammatory bowel disease: what are the data?
    Côté-Daigneault J; Bouin M; Lahaie R; Colombel JF; Poitras P
    United European Gastroenterol J; 2015 Oct; 3(5):419-28. PubMed ID: 26535119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thiopurine Monotherapy Is Effective in Maintenance of Mild-Moderate Inflammatory Bowel Disease.
    Barber GE; Hendler S; Choe M; Keyashian K; Lechner S; Limketkai BN; Limsui D
    Dig Dis Sci; 2022 Apr; 67(4):1287-1294. PubMed ID: 33755823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The role of biologic therapy in the treatment of extraintestinal manifestations and complications of inflammatory bowel disease].
    Kujundzić M
    Acta Med Croatica; 2013 Apr; 67(2):195-201. PubMed ID: 24471303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammatory Bowel Disease in Childhood and Adolescence.
    Däbritz J; Gerner P; Enninger A; Claßen M; Radke M
    Dtsch Arztebl Int; 2017 May; 114(19):331-338. PubMed ID: 28597827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New advances in the treatment of inflammatory bowel disease].
    Chaparro M
    Gastroenterol Hepatol; 2013 Oct; 36 Suppl 2():21-9. PubMed ID: 24160949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of blood concentration of biologics on endoscopic inactivity in inflammatory bowel disease: A systematic review.
    Cao WT; Huang R; Jiang KF; Qiao XH; Wang JJ; Fan YH; Xu Y
    World J Gastroenterol; 2021 Mar; 27(9):886-907. PubMed ID: 33727776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Inflammatory bowel diseases : Crohn's disease and ulcerative colitis].
    Fischer S; Rath T; Neurath MF
    Internist (Berl); 2018 Jul; 59(7):681-693. PubMed ID: 29872891
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.